Akira Takahashi

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Combination Therapy

Peritoneal Dialysis

Prognostic Factors

Top Venues

The Journal of dermatology

Dermatologic therapy

International journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Shunichi Jinnai, Eiji Nakano, Naoya Yamazaki
Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. The Journal of dermatology (2022)
Mao Okumura, Eiji Nakano, Kenjiro Namikawa, Akira Takahashi, Yutaka Fujiwara, Naoya Yamazaki
Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study. International journal of dermatology (2021)
Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Shunichi Jinnai, Kenta Nakama, Keita Tsutsui, Yusuke Muto, Haruki Mizuta, Naoya Yamazaki
Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. The Journal of dermatology 47 (11) (2020)
Eiji Nakano, Akira Takahashi, Kenjiro Namikawa, Yusuke Muto, Shunichi Jinnai, Yuta Kage, Haruki Mizuta, Arata Tsutsumida, Naoya Yamazaki
Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. The Journal of dermatology 47 (6) (2020)
Haruki Mizuta, Eiji Nakano, Akira Takahashi, Takafumi Koyama, Kenjiro Namikawa, Naoya Yamazaki
Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatologic therapy 33 (3) (2020)
Akira Takahashi, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki
Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma. The Journal of dermatology 47 (3) (2019)